NNOX - Nano-X Imaging lower 10% on additional information request by FDA on Nanox.ARC version

Nano-X Imaging (NNOX) received additional information requests from the FDA for the review of its single-source version of the Nanox.ARC which require the Company to address certain deficiencies and questions, including the intended use of the Nanox.ARC and the comparability of the Nanox.ARC to the predicate device.The Company plans to respond to these requests promptly.The company will continue to optimize and develop features of the Nanox.ARC, and plans to submit an additional 510(k) premarket notification to the FDA with respect to the multiple-source Nanox.ARC and the Nanox.CLOUD during 2021.If cleared by the FDA and authorized by similar regulatory agencies in other jurisdictions, the Company is targeting shipment of 1,000 Nanox Systems by the end of the first quarter of 2022, with the goal to finalize deployment of the initial 15,000 Nanox Systems by the end of 2024.Press Release

For further details see:

Nano-X Imaging lower 10% on additional information request by FDA on Nanox.ARC version